OPC-1 is under clinical development by Lineage Cell Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect OPC-1’s likelihood of approval (LoA) and phase transition for Acute Spinal Cord Injury took place on 30 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OPC-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

OPC-1 overview

AST-OPC1 is under development for the treatment of acute spinal cord injury. It is administered through injection (parenteral). The therapeutic candidate contains human embryonic stem cells (hESCs)-derived from oligodendrocyte progenitor cells. The drug candidate was also under development for the treatment of Alzheimer's disease, Canavan disease, cerebral ischemia and multiple sclerosis .

Lineage Cell Therapeutics overview

Lineage Cell Therapeutics (Lineage) formerly known as BioTime, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. The company lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration, Opc1 in acute spinal cord injury, and Vac2 for non-small cell lung cancer. The company has subsidiaries in Israel, Singapore, and the US. Lineage is headquartered in Carlsbad, California, the US.

Quick View OPC-1 LOA Data

Report Segments
  • Innovator
Drug Name
  • OPC-1
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.